Keyphrases
Prostate Cancer
100%
Clinical Outcomes
51%
Melanoma
36%
Docetaxel
29%
Tumor-initiating Cells
24%
GATA2
23%
Tumor
23%
Chemotherapy
23%
Chemotherapy Resistance
22%
Adjuvant Interferon
21%
Resectable Gastric Cancer
21%
Bladder Cancer
21%
Acquired Resistance
19%
Stem Cells
19%
Gastric Cancer Patients
17%
Umbrella Cells
17%
Melanoma Patients
16%
Bladder Tumor
16%
Confidence Interval
15%
Prostate Cancer Patients
15%
Primary Tumor
15%
Prostate Cancer Cells
15%
Metastatic Urothelial Cancer
15%
Median Survival Time
14%
Temozolomide
14%
Hormone-independent
14%
S100 Proteins
14%
Radiation Therapy
14%
High-risk Melanoma
14%
Sarcoma
14%
Nuclear factor-B
14%
Lung Cancer
14%
Human Breast Cancer Cells
14%
Adjuvant Chemotherapy
14%
Urothelial
14%
E2F Transcription Factor 1 (E2F1)
14%
Chromosomal Instability
14%
Tyrosinase
14%
Upper Tract Urothelial Carcinoma
14%
Patient-derived Xenograft
14%
Urothelium
13%
Cisplatin
12%
Urinary Bladder
12%
S100
12%
Overall Survival
12%
Tumor-initiating
11%
Quantitative PCR
11%
Therapeutic Strategies
11%
Tumor Progression
11%
Radiotherapy
11%
Medicine and Dentistry
Prostate Cancer
51%
Melanoma
49%
Radiation Therapy
32%
Diseases
32%
Cancer Stem Cell
30%
Neoplasm
30%
Urothelial Cancer
24%
Bladder Cancer
24%
Metastatic Carcinoma
22%
Carcinogenesis
20%
Cisplatin
18%
Bladder
16%
Transcription Factor GATA 2
16%
Bladder Tumor
15%
Interferon
15%
Primary Tumor
14%
Median Survival Time
14%
Pelvis
14%
Messenger RNA
14%
Abdominal Cancer
14%
Tumor Progression
13%
Cytokeratin
11%
Neoadjuvant Chemotherapy
10%
Cystectomy
10%
Local Therapy
10%
Gemcitabine
10%
Brain Metastasis
10%
Brain Radiation
10%
Temozolomide
10%
Mitomycin
10%
Malignant Neoplasm
10%
Retroperitoneal Lymph Node Dissection
10%
Overall Survival
10%
Cancer Cell
9%
Clinical Trial
9%
Lymph Node
9%
Tegafur
8%
Recurrent Disease
8%
Cancer Growth
8%
Paclitaxel
8%
Xenograft
7%
Urothelium
7%
Alternative Complement Pathway C3 C5 Convertase
7%
Triple Negative Breast Cancer
7%
Stathmin
7%
Ipilimumab
7%
Somatomedin
7%
Subcutaneous Injection
7%
Gastrectomy
7%
Head and Neck Cancer
7%
Pharmacology, Toxicology and Pharmaceutical Science
Prostate Cancer
73%
Neoplasm
53%
Melanoma
49%
Diseases
37%
Chemotherapy
34%
Docetaxel
29%
Malignant Neoplasm
26%
Bladder Cancer
23%
Transcription Factor GATA 2
23%
Interferon
22%
Breast Cancer
17%
Messenger RNA
16%
Overall Survival
15%
Protein S 100
14%
Tyrosinase
14%
Cytokeratin
11%
Carcinogenesis
11%
Brain Metastasis
10%
Temozolomide
10%
Recurrent Disease
10%
Drug Resistance
9%
Proteasome
9%
Prostate Specific Antigen
9%
Proteasome Inhibitor
8%
Primary Tumor
8%
Taxane
8%
Bladder Tumor
8%
Paclitaxel
8%
Tumor Growth
8%
Antitumor Activity
8%
Epidermal Growth Factor Receptor 2
7%
Cancer Growth
7%
Tau Protein
7%
Interleukin 6
7%
Skin Manifestation
7%
Ipilimumab
7%
Liver Cell Carcinoma
7%
Bortezomib
7%
Stathmin
7%
Cisplatin
7%
Antimitotic Agent
7%
Progastrin Releasing Peptide
7%
Thymidylate Synthase
7%
Mitomycin
7%
Alternative Complement Pathway C3 C5 Convertase
7%
Nuclear Factor
7%
Tegafur
7%
Head and Neck Cancer
7%
Plasma Protein
7%
Gamma Urogastrone
7%